Research programme: zinc metallochaperones - Z53 Therapeutics

Drug Profile

Research programme: zinc metallochaperones - Z53 Therapeutics

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rutgers Cancer Institute of New Jersey; SUNY Upstate Medical University
  • Developer Z53 Therapeutics
  • Class Antineoplastics; Small molecules; Zinc compounds
  • Mechanism of Action Tumour suppressor protein p53 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Solid tumours

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top